Emerging Therapies in the Preventive Care of Migraine

Welcome to the registration website for
The Promise of CGRP Antibodies
to Change Practice in Migraine Treatment

Join us for this interactive educational event and earn 1.5 credit hours of continuing education. Food and refreshments will be served.

Saturday, November 18, 2017
5:15 pm - 6:45 pm

JW Marriott Desert Ridge Resort & Spa
Grand Canyon 9-13
5350 E. Marriott Drive
Phoenix, AZ 85054

Dear Colleague,

We are excited to invite you to a new experience in learning! Please join us in an engaging and highly interactive educational multimedia gallery on Saturday evening, November 18, 2017.

My co-presenters, Dr. Richard Lipton and Dr. Andrew Charles, will join me to answer any questions you may have as you navigate through the four poster gallery areas. The gallery has been created to allow you the opportunity to experience the delivery of information through interactive multimedia technology shared with you both visually and through interactivity on an iPad device provided to you upon arrival. The display allows you to move at your own pace through the educational experience, and covers today’s clinical environment and the challenges associated with the recognition and management of episodic and chronic migraine, and with effective preventive treatment and prophylaxis of these headache disorders.

Following your interactive gallery experience, we invite you to take a seat and hear additional information presented by myself, Dr. Lipton, and Dr. Charles. Together we will highlight the challenges currently encountered by patients and clinicians when implementing preventive treatment for migraine, and share with you the promising new therapies on the horizon and how they compare with currently available therapies. Presentations will include insights and understanding about how these new therapies work, the unique features of the CGRP monoclonal antibodies, how these four new agents have performed in clinical trials, and, most importantly, how they may impact practice.

Our session will conclude with what we anticipate will be a lively exchange between the panel and the audience, so I encourage you to join in on this discussion.

I look forward to seeing you there.

David W. Dodick, MD


TARGET AUDIENCE
This activity is designed for health care professionals who treat patients with headache disorders.

LEARNING OBJECTIVES
Upon completion of this educational activity, participants should be able to:
  • Identify the unmet clinical needs resulting from ineffective preventive treatments
  • Describe the role of calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine
  • Compare and contrast emerging treatments currently in clinical trials which show promise to improve patient outcomes in the preventive treatment of episodic and chronic migraine
FACULTY
David W. Dodick, MD David W. Dodick, MD – Chair
Professor of Neurology
Department of Neurology
Mayo Clinic
Phoenix, Arizona
Andrew C.  Charles, MD Andrew C. Charles, MD
Professor of Neurology
UCLA School of Medicine
Los Angeles, California
Richard  B. Lipton, MD Richard B. Lipton, MD
Professor of Neurology
Professor of Epidemiology and Population Health
Professor of Psychiatry and Behavioral Sciences
Albert Einstein College of Medicine
Bronx, New York

AGENDA

5:15 pm Registration Reception with Food and Refreshments
5:30 pm – 6:10 pm Interactive gallery display with David W. Dodick, MD; Andrew C. Charles, MD; Richard B. Lipton, MD
  • Interactive Poster 1: The Reality of Migraine: What Challenges Are You and Your Patients Facing in Today’s Clinical Environment?
  • Interactive Poster 2: Preventive Treatment in Migraine: How Much Do You Know About Migraine Prophylaxis?
  • Interactive Poster 3: The Science of Migraine: Why Do You Need to Understand the Pathophysiology of Headache?
  • Interactive Poster 4: Evolving Strategies in Migraine Prevention: What Do You Know About CGRP Inhibitors?
6:10 pm – 6:35 pm David W. Dodick, MD
  • A Look at the Unique Features of CGRP mAbs While Examining New Data Across Current Clinical Trials
David W. Dodick, MD; Andrew C. Charles, MD; Richard B. Lipton, MD
  • Moving from the Bench to Practice: Expert Perspectives on the Future of Prevention in Migraine
6:35 pm – 6:45 pm David W. Dodick, MD; Andrew C. Charles, MD; Richard B. Lipton, MD
Moderated Panel Discussion and Audience Questions

ACCREDITATION  
MediCom Worldwide, Inc. CME Credit
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.5 contact hours of Continuing Education Credit.
Universal Activity Number: 827-0000-17-176-L01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
MediCom Worldwide, Inc. Nursing Credit
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.5 contact hours. Program Number: 17-176-067

DISCLOSURE
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

AMERICANS WITH DISABILITIES ACT/SPECIAL NEEDS
MediCom Worldwide, Inc. is committed to equality of educational opportunity and does not discriminate against applicants, students, or employees on the basis of race, color, religion, sex, national origin, age, disability, veterans status, or sexual orientation. If you require reasonable accommodations for a disability in order to participate fully in this continuing education activity, please call 800-408-4242 no later than 14 days prior to the activity.

INSTRUCTIONS FOR PARTICIPATION AND CREDIT
There are no fees for participating in this activity. In order to receive credit, all participants must complete the Activity Evaluation Form following the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment portion of the form to qualify for CE credit. CME/CNE certificates will be e-mailed 4 weeks following receipt of a completed, qualified form. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

If you have any questions regarding this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, ext. 128 or email lisa@medicaled.com

MediCom Worldwide, Inc. Provided by
MediCom Worldwide, Inc.

Supported by an educational grant from Teva Pharmaceuticals